How a big biotech’s start-up gamble went wrong
Behind the Money
The Importance of Gene Sequencing Technology in Cancer Screening
Illumina's new acquisition, Grail, is a biotech startup that's in the process of developing another potentially revolutionary technology. What they're working on is a test that can screen for lots of different types of cancer by analyzing a person's blood. Picture what that could mean for Illumina, a company that would not only have a near monopoly on gene sequencing technology, but also a major cancer screening test.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
